ERAS stock news · Erasca, Inc.

Stories about Erasca, Inc. (ERAS) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ERAS

Follow Erasca, Inc. (ERAS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Nov 12, 2026, 4:53 PM ET · Trial
Erasca shared its third-quarter results for 2026, noting FDA Fast Track approval for its drug ERAS-0015.
Good for ERAS
Erasca had $947.8 million in cash and securities on September 30, up from $341.8 million on December 31, 2025. FDA Fast Track status also supports planned trials.
Oct 16, 2026, 9:08 AM ET · New boss
Erasca, Inc. is changing its leadership, including letting go of its COO and adding new directors.
Neutral
Erasca is shifting the COO's duties to other leaders before his November 2, 2026 departure. The filing gives no update on drug progress, so the outlook is unchanged.